Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up

• Váldodahkkit: Antonio Lacquaniti (Dahkki), Patrizio Pasqualetti (Dahkki), Teresa Casuscelli di Tocco (Dahkki), Susanna Campo (Dahkki), Stefania Rovito (Dahkki), Maurizio Bucca (Dahkki), Antonino Ragusa (Dahkki), Paolo Monardo (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: The Korean Society of Nephrology, 2020-09-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Background : : Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have...